, Volume 45, Supplement 1, pp S23–S28 | Cite as

Evaluation of risk factors for development of complications in Type II diabetes in Europe




The Cost of Diabetes in Europe-Type II study is the first large coordinated attempt to measure the current standard of care and determine the costs of managing patients with Type II (non-insulin-dependent) diabetes mellitus.


The study evaluated glycaemic control, blood lipid levels and blood pressure, all of which are risk factors for complications. Records of these clinical characteristics were collected from over 7000 patients during the 6-month study period.


The mean HbAlc value for the entire study population was 7.5%, ranging from 7.0% in Sweden to 7.8% in the United Kingdom. Only 31% of individuals achieved good glycaemic control (HbAlc≤=6.5%) according to current European guidelines. Only 64% of the total study population were tested for HbAlc values at least once within the 6-month study period (ranging from 49% in Spain to 71% in the UK), although HbAlc testing every 3 months is recommended for all patients, by European Diabetes Policy Group guidelines. The majority of patients had borderline total cholesterol values, with a mean value of 5.7 mmol/1. Overall, 21% of patients were classified as having low risk cholesterol levels (<4.8 mmol/1). Good triglyceride levels (<1.7 mmol/1) were achieved by 47% of the total study population. During the study period, 81 % of patients had their blood pressure measured, with 35% and 53.3% of the patients reaching the recommended targets for systolic and diastolic blood pressure, respectively.


This study showed that a high proportion of patients with risk factors for diabetes-related complications are not adequately controlled. Improvements in disease management and monitoring are therefore required to ensure that guideline targets are met, thus reducing the long-term complications of Type II diabetes.


Type II diabetes management monitoring control 



Cost of Diabetes in Europe-Type II


European Diabetes Policy Group


fasting plasma glucose


total cholesterol




systolic blood pressure


distolic blood pressure


  1. 1.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434–444CrossRefPubMedGoogle Scholar
  2. 2.
    Perneger TV, Brancati FL, Whelton PK, Klag MJ (1994) End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 121: 912–918CrossRefPubMedGoogle Scholar
  3. 3.
    UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type II diabetes (UKPDS 33). Lancet 352: 837–853CrossRefGoogle Scholar
  4. 4.
    UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with metformin on complications in overweight patients with Type II diabetes (UKPDS 34). Lancet 352: 854–865CrossRefGoogle Scholar
  5. 5.
    UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in Type II diabetes (UKPDS 38). BMJ 352: 703–713CrossRefGoogle Scholar
  6. 6.
    UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and Captopril in reducing risk of both macrovascular and microvascular complications in Type II diabetes (UKPDS 39). BMJ 317: 713–720CrossRefPubMedCentralGoogle Scholar
  7. 7.
    American Diabetes Association (1998) Implications of the United Kingdom prospective diabetes study. Diabetes Care 21: 2180–2184CrossRefGoogle Scholar
  8. 8.
    Diabetes Care and Research in Europe (1990) The St Vincent Declaration. Diabetic Med 7: 360CrossRefGoogle Scholar
  9. 9.
    Massi-Benedetti M (2000) Cost of diabetes in Europe-Type II (CODE 2) study. Diabetologia supplement [this issue]Google Scholar
  10. 10.
    Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in Type II diabetes mellitus. Arch Intern Med 159: 1873–1880CrossRefPubMedGoogle Scholar
  11. 11.
    Williams R, Van Gaal L, Lucioni C (2000) Assessing the impact of complications on the costs of Type II diabetes. Diabetologia supplement [this issue]Google Scholar
  12. 12.
    Jönsson B (2000) Revealing the cost of Type II diabetes in Europe. Diabetologia supplement [this issue]Google Scholar
  13. 13.
    Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614–620CrossRefPubMedGoogle Scholar
  14. 14.
    European Diabetes Policy Group (1999) Guidelines for diabetes care: a desktop guide to type II diabetes mellitus. International Diabetes Federation (European Region). Diabet Med 16: 716–730CrossRefGoogle Scholar
  15. 15.
    Sacks FM, Pfeffer MA, Moye LA et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001–1009CrossRefPubMedGoogle Scholar
  16. 16.
    Howard BV, Robbins DC, Sievers ML et al. (2000) LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vase Biol 3: 830–835CrossRefGoogle Scholar
  17. 17.
    Kris-Etherton PM, AHA Science Advisory (1999) Monounsaturated fatty acids and risk of cardiovascular disease. American Heart Association. Nutrition Committee. Circulation 100: 1253–1258CrossRefPubMedGoogle Scholar
  18. 18.
    Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S (1997). JAMA 278: 1663–1669CrossRefPubMedGoogle Scholar
  19. 19.
    Ohkubo Y, Kishikawa H, Araki E et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomised prospective 6-year study. Diabetes Res Clin Pract 28: 103–117CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  1. 1.Diabetes CenterFachklinik Bad HeilbrunnBad HeilbrunnGermany
  2. 2.Primary Health Care Centre La MinaBarcelonaSpain
  3. 3.Unit 258INSERMVillejuifFrance

Personalised recommendations